| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net cash flow provided by (used in) investing activities | 232,903 | 144,500 |
| Proceeds from options exercised under esop | - | 100 |
| Proceeds from long-term debt, net of issuance costs | 73,022 | 73,022 |
| Issuance of class a ordinary shares, net of transaction costs | 0 | 0 |
| Stamp duty on capital injection from moonlake to moonlake ag | 0 | 0 |
| Proceeds from options exercised-Equity Incentive Plan | 480 | - |
| Proceeds from options exercised-Employee Stock Option Plan ESOP | 100 | - |
| Net cash flow provided by financing activities | 73,602 | 73,122 |
| Effect of movements in exchange rates on cash held | 1,018 | 1,303 |
| Net change in cash and cash equivalents | 170,310 | 126,255 |
| Cash and cash equivalents at beginning of period | 180,426 | - |
| Cash and cash equivalents at end of period | 350,736 | - |
MoonLake Immunotherapeutics (MLTX)
MoonLake Immunotherapeutics (MLTX)